Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Manidipine 6300. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.70 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.70 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.70 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.70 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.70 |
| ▸ | HTR1A | P08908 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Manidipine 6300 SCHEMBL29801590 | 1.00 | MAPT (0.70) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL49368 | 1.00 | MAPT (0.70) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL247919 | 0.99 | ADRA1A (0.71) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL137617 | 0.99 | ADRA1A (0.71) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL1491200 | 0.99 | ADRA1A (0.71) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL137616 | 0.99 | ADRA1A (0.71) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL6275097 | 0.99 | ADRA1A (0.71) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL28185730 | 0.99 | MAPT (0.69) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL678249 | 0.98 | MAPT (0.68) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL28927600 | 0.98 | ADRA1A (0.70) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1452 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714447-A1 | DRUG COMBINATIONS OF BCL-XL INHIBITORS FOR TREATMENT OF CANCER | Stichting Amsterdam UMC (NL) | 2026-03-25 | — | — | EP | claimed |
| EP-4640238-A1 | THERAPEUTIC AGENT FOR PULMONARY DISEASE, HEPATIC DISEASE OR RENAL DISEASE, WHICH CONTAINS PGAM-CHK1 BINDING INHIBITOR | Kyoto University (JP) | 2025-10-29 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-20250003952-A1 | SENOLYTIC DRUG SCREENING METHOD AND SENOLYTIC DRUG | KYOTO UNIVERSITY (JP) | 2025-01-02 | — | — | US | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | claimed |
| EP-4400117-A1 | SENOLYTIC DRUG SCREENING METHOD AND SENOLYTIC DRUG | Kyoto University (JP) | 2024-07-17 | — | — | EP | claimed |
| WO-2024135719-A1 | THERAPEUTIC AGENT FOR PULMONARY DISEASE, HEPATIC DISEASE OR RENAL DISEASE, WHICH CONTAINS PGAM-CHK1 BINDING INHIBITOR | 国立大学法人京都大学 | 2024-06-27 | — | — | WO | claimed |
| EP-4243805-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | Gbiotech S.À.R.L. (CH) | 2023-09-20 | — | — | EP | claimed |
| US-20230124862-A1 | BISMUTH THIOL COMPOUNDS AND COMPOSITIONS AND METHODS OF TREATING MICROBIAL CO-INFECTIONS | MICROBION CORPORATION | 2023-04-20 | — | — | US | claimed |
| EP-1343506-A1 | PHARMACEUTICAL FORMULATION CONTAINING PYRAZOLO 4,3-D]PYRIMIDINES AND ANTITHROMBOTIC AGENTS, CALCIUM-ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES | MERCK PATENT GmbH (DE) | 2003-09-17 | — | — | EP | claimed |
| CN-1436077-A | stable pharmaceutical composition containing calcium blocker | SANKYO CO (JP) | 2003-08-13 | — | — | CN | claimed |
| WO-2003039521-A1 | SOLID, STABILIZED, PROMPT- AND/OR MODIFIED-RELEASE THERAPEUTICAL SYSTEMS FOR THE ORAL ADMINISTRATION OF LIQUID ACTIVE PRINCIPLES, EXCIPIENTS OR FOODSTUFFS | FARMATRON LTD. (GB) | 2003-05-15 | — | — | WO | claimed |
| WO-2002049649-A2 | PHARMACEUTICAL FORMULATION CONTAINING THIENOPYRIMIDINES AND ANTITHROMBOTICS, CALCIUM ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES (2) | MERCK PATENT GMBH (DE) | 2002-06-27 | — | — | WO | claimed |
| WO-2002049650-A2 | PHARMACEUTICAL FORMULATION CONTAINING THIENOPYRIMIDINES AND ANTITHROMBOTICS, CALCIUM ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-06-27 | — | — | WO | claimed |
| WO-2002049651-A1 | PHARMACEUTICAL FORMULATION CONTAINING PYRAZOLO[4,3-D]PYRIMIDINES AND ANTITHROMBOTIC AGENTS, CALCIUM-ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-06-27 | — | — | WO | claimed |
| CN-1315945-A | Nitrate salts of antihypertensive drugs | NICOX SA (FR) | 2001-10-03 | — | — | CN | claimed |
| EP-1087953-A1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX S.A. (FR) | 2001-04-04 | — | — | EP | claimed |
| CN-1248162-A | Topical pharmaceutical composition containing cholinergic agent or calcium channel blocker | MICHAEL ALBERT KAMM (GB) | 2000-03-22 | — | — | CN | claimed |
| WO-1999067231-A1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX S.A. (FR) | 1999-12-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124862-A1 | BISMUTH THIOL COMPOUNDS AND COMPOSITIONS AND METHODS OF TREATING MICROBIAL CO-INFECTIONS | MPST, TST, TPMT | CACNA1C 4183/4885MAPT 30/4885CYP1A2 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.